Metastatic Breast Cancer

Study: Enhertu shows promising results for HER2-low and HER2-ultralow metastatic breast cancer

Recent study results show that a new targeted treatment works better than standard chemotherapy for people with metastatic hormone receptor-positive breast cancers with low or ultralow HER2 status. (Posted 5/15/25)

Study: Use of cannabis for cancer symptom management

Among people with cancer, interest in the use of cannabis to manage cancer symptoms and treatment side effects is high. The world's leading professional organization of oncologists has published strategies to help adults with cancer and their healthcare providers have open, nonjudgmental discussions about the use of cannabis to manage cancer symptoms. (Posted 9/27/24)

Este artículo está disponible en español.

Study: Combining two anti-HER2 drugs improves outcomes more effectively than one

Combining two anti-HER2 drugs increased the time until cancer returned for people with locally advanced or metastatic HER2-positive breast cancer compared to people who received just one anti-HER2 drug. People whose breast cancer had metastasized to the brain also benefitted from the two combined drugs. (Posted 9/17/24)

Este artículo está disponible en español.

Update: News from the FDA: Updates on breast cancer treatment

The FDA updates the risks of using BioZorb Markers and approves a new imaging drug for breast cancer. (Posted 8/16/24)

Este artículo está disponible en español.

Topic: Acupressure for cancer symptom relief

Acupressure is a safe treatment that can be used to relieve some symptoms of cancer and side effects of treatment. Light pressure applied to key points on the body may help with fatigue, sleep, nausea and possibly other symptoms as well. (Posted 8/1/24)

Este artículo está disponible en español.

Topic: The drug Enhertu is FDA-approved for any advanced or metastatic HER2-positive tumors

The FDA granted accelerated approval of Enhertu for people with any HER2-positive tumor that is metastatic or cannot be surgically removed. Eligible patients must have had previous treatment such as chemotherapy or hormone therapy. (Posted 7/19/24)

Este artículo está disponible en español.

Topic: Experts call for early palliative care for cancer patients

People with cancer need support and care not only at the end of life but from the time of diagnosis. At the 2024 American Society of Clinical Oncology (ASCO) annual meeting, the organization’s president urged cancer healthcare professionals to make palliative care central to cancer treatment. (Posted 7/17/24)

Este artículo está disponible en español.

Study: Genetic testing among people with cancer can find mutations that may affect treatment and prevention

Despite national guidelines recommending genetic testing, less than 10 percent of eligible patients had genetic testing within two years after their cancer diagnosis. Among those who had testing, 10-30 percent had an inherited mutation that could affect their medical care. (Posted 3/15/2024)

Este artículo está disponible en español.

Update: News from the FDA– new breast cancer treatment, thermography warning and implant screening updates

This XRAY review is a summary of FDA breast cancer updates from July to December 2023.  This includes a new drug approval and two consumer updates. (Posted 2/21/24)

Este artículo está disponible en español.

Update: New drug combination for the second treatment of some HR-positive advanced breast cancers

The FDA approved Truqap plus Faslodex for the treatment of metastatic hormone receptor-positive (HR-positive), HER2-negative breast cancer that returned or worsened after treatment with hormone therapy. The approval is for treating cancers in people whose tumors had a mutation in one of three genes. For people with one of these mutations, Truqap improved the time until their cancer came back or got worse.  (Posted 2/9/24)

Este artículo está disponible en español.